LOGO

Vaxine actively protects its intellectual property through development of patents, trademarks and commercial secrets

• Advax(TM) is the trademark for a family of plant sugar-based vaccine adjuvants developed by Vaxine Pty Ltd
• To protect the Advax(TM) family of adjuvants, Vaxine has been granted multiple US and international patents. As new data is generated and advances made, Vaxine continues to apply for new patents over these technology improvements.
• In addition to its Advax(TM) patent coverage, Vaxine also holds international patents over vaccine technology to prevent type 1 (autoimmune) diabetes.
• Vaxine is currently actively seeking additional licensing and/or development partners with respect to its vaccine technologies